Global Health Journalism that Informs Decisions
Merck has selected Kiambu-based Universal Corporation Limited to produce generic alimatravir for 129 countries if the once-monthly PrEP pill—expected to cost just $5 per person annually—succeeds in trials and is approved.
It is a modest 1% decline but researchers found Kenya's treatment trend diverged more sharply from its historical pattern than any other country studied.
Kenya has begun to rollout a breakthrough drug for HIV prevention. The move would be a game changer in the country’s battle against HIV, health...
The Global Fund will give Kenya the funds to purchase lenacapavir—an injection given twice a year to people who are HIV-negative to prevent infection...
